X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5386) 5386
Book Review (908) 908
Publication (348) 348
Newsletter (109) 109
Conference Proceeding (20) 20
Book Chapter (13) 13
Newspaper Article (12) 12
Magazine Article (5) 5
Dissertation (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
capecitabine (4680) 4680
humans (4599) 4599
index medicus (4567) 4567
oncology (3544) 3544
female (3423) 3423
deoxycytidine - analogs & derivatives (2836) 2836
middle aged (2814) 2814
aged (2703) 2703
fluorouracil - analogs & derivatives (2524) 2524
antineoplastic combined chemotherapy protocols - therapeutic use (2492) 2492
chemotherapy (2389) 2389
male (2374) 2374
deoxycytidine - administration & dosage (2258) 2258
fluorouracil - administration & dosage (2191) 2191
adult (2190) 2190
cancer (1791) 1791
treatment outcome (1636) 1636
antineoplastic combined chemotherapy protocols - adverse effects (1198) 1198
breast neoplasms - drug therapy (1133) 1133
care and treatment (1014) 1014
fluorouracil (992) 992
oxaliplatin (964) 964
deoxycytidine - adverse effects (951) 951
5-fluorouracil (946) 946
colorectal cancer (936) 936
organoplatinum compounds - administration & dosage (927) 927
aged, 80 and over (923) 923
colorectal neoplasms - drug therapy (901) 901
breast cancer (896) 896
metastasis (888) 888
disease-free survival (885) 885
therapy (875) 875
fluorouracil - adverse effects (860) 860
neoplasm staging (764) 764
research (751) 751
medicine & public health (746) 746
breast neoplasms - pathology (741) 741
pharmacology & pharmacy (729) 729
deoxycytidine - therapeutic use (725) 725
neoplasm metastasis (721) 721
trial (712) 712
antineoplastic combined chemotherapy protocols - administration & dosage (708) 708
drug administration schedule (670) 670
survival (670) 670
bevacizumab (656) 656
drug therapy (640) 640
fluorouracil - therapeutic use (616) 616
antimetabolites, antineoplastic - administration & dosage (575) 575
hematology, oncology and palliative medicine (561) 561
retrospective studies (559) 559
combination (554) 554
clinical trials (545) 545
adenocarcinoma - drug therapy (533) 533
survival rate (532) 532
prognosis (528) 528
capecitabine - administration & dosage (526) 526
colorectal neoplasms - pathology (526) 526
administration, oral (524) 524
antimetabolites, antineoplastic - therapeutic use (522) 522
leucovorin (513) 513
carcinoma (500) 500
antineoplastic agents - therapeutic use (494) 494
1st-line treatment (489) 489
stomach neoplasms - drug therapy (488) 488
antineoplastic agents (485) 485
camptothecin - analogs & derivatives (474) 474
analysis (473) 473
surgery (472) 472
survival analysis (472) 472
antimitotic agents (462) 462
antimetabolites, antineoplastic - adverse effects (455) 455
irinotecan (454) 454
cisplatin (451) 451
radiotherapy (445) 445
cancer research (438) 438
health aspects (434) 434
docetaxel (429) 429
chemotherapy, adjuvant (424) 424
leucovorin - administration & dosage (422) 422
dosage and administration (421) 421
toxicity (417) 417
phase-ii (407) 407
camptothecin - administration & dosage (406) 406
gemcitabine (404) 404
taxoids - administration & dosage (397) 397
tumors (397) 397
follow-up studies (386) 386
oral capecitabine (385) 385
paclitaxel (385) 385
trastuzumab (380) 380
metastatic colorectal-cancer (377) 377
patients (371) 371
antineoplastic agents - administration & dosage (367) 367
cisplatin - administration & dosage (367) 367
dose-response relationship, drug (366) 366
phase-ii trial (364) 364
cancer patients (363) 363
kaplan-meier estimate (363) 363
adenocarcinoma (362) 362
cancer therapies (358) 358
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5242) 5242
Japanese (125) 125
Chinese (42) 42
French (29) 29
German (23) 23
Russian (15) 15
Spanish (12) 12
Italian (10) 10
Hungarian (5) 5
Czech (4) 4
Dutch (3) 3
Korean (3) 3
Polish (3) 3
Danish (2) 2
Portuguese (2) 2
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Cancer Institute, ISSN 0027-8874, 4/2008, Volume 100, Issue 8, pp. 542 - 551
Background Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of... 
THERAPY | GEPARDUO | ONCOLOGY | PROGNOSIS | CARCINOMA | CHEMOTHERAPY | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Vinblastine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Breast Neoplasms - chemistry | Carcinoma, Ductal, Breast - drug therapy | Fluorouracil - administration & dosage | Vinblastine - analogs & derivatives | Mastectomy, Segmental | Adult | Female | Breast Neoplasms - diagnostic imaging | Chemotherapy, Adjuvant | Doxorubicin - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Deoxycytidine - administration & dosage | Ultrasonography, Mammary | Treatment Outcome | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Aged | Carcinoma, Lobular - drug therapy | Patient Compliance | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Germany | Chemotherapy | Breast cancer | Drug therapy | Comparative analysis | Health aspects | Cancer | Side effects | Toxicity | Clinical outcomes | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3639 - 3648
Journal Article
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3786 - 3793
Purpose Data concerning the prevalence of and outcomes related to thromboembolic events (TEs) in patients with advanced gastroesophageal cancer who are... 
CISPLATIN-BASED CHEMOTHERAPY | PHASE-III TRIAL | BREAST-CANCER | FLUOROURACIL PLUS OXALIPLATIN | ONCOLOGY | ADVANCED ESOPHAGOGASTRIC CANCER | TESTICULAR CANCER | VASCULAR EVENTS | CENTRAL VENOUS CATHETERS | 1ST-LINE THERAPY | METASTATIC COLORECTAL-CANCER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Anticoagulants - administration & dosage | Thromboembolism - chemically induced | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Thromboembolism - epidemiology | Warfarin - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Incidence | Esophageal Neoplasms - complications | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Odds Ratio | Catheterization, Central Venous - adverse effects | Stomach Neoplasms - complications | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Thromboembolism - etiology | Stomach Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | United Kingdom - epidemiology | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3234 - 3241
Journal Article
Cancer, ISSN 0008-543X, 10/2011, Volume 117, Issue 20, pp. 4617 - 4622
BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin... 
second‐line and temozolomide | chemotherapy | neuroendocrine cancer | PDEC | second-line and temozolomide | TRACT | PHASE-II TRIAL | ETOPOSIDE | NEUROENDOCRINE TUMORS | CISPLATIN | ONCOLOGY | SMALL-CELL CARCINOMA | Capecitabine | Humans | Middle Aged | DNA Repair Enzymes - genetics | Male | Antineoplastic Agents, Alkylating - administration & dosage | DNA Repair - genetics | Promoter Regions, Genetic - genetics | Bevacizumab | Cisplatin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Carcinoma, Neuroendocrine - chemistry | Retrospective Studies | Dacarbazine - administration & dosage | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Neuroendocrine - genetics | Etoposide - administration & dosage | Treatment Outcome | DNA Methylation - genetics | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Aged | Deoxycytidine - analogs & derivatives | Salvage Therapy - methods | Endocrine gland cancer | Care and treatment | Dosage and administration | Temozolomide | Research | Carcinoma | Medical treatment | Medical services | Etoposide | Patients | Survival | Cisplatin | Metastases | Chemotherapy | Methylation | Cancer | Index Medicus | Abridged Index Medicus | temozolomide | second-line | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
PROJECT PROTOCOL B-27 | TRIAL | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | THERAPY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | PHASE-III | DISEASE | DOCETAXEL | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3520 - 3526
Journal Article
Cancer Research, ISSN 0008-5472, 02/2012, Volume 72, Issue 3, pp. 779 - 789
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation,... 
XENOGRAFT MODELS | MELANOMA | PIK3CA GENE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | IN-VIVO | WILD-TYPE BRAF | THYROID-CARCINOMA CELLS | B-RAF | KINASE INHIBITOR | RAF/MEK/ERK PATHWAY | Erlotinib Hydrochloride | Area Under Curve | Capecitabine | Colorectal Neoplasms - genetics | Humans | Indoles - administration & dosage | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Indoles - pharmacology | Quinazolines - administration & dosage | Phosphorylation - drug effects | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Camptothecin - analogs & derivatives | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | HCT116 Cells | Kaplan-Meier Estimate | Sulfonamides - pharmacology | Blotting, Western | Sulfonamides - pharmacokinetics | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Indoles - pharmacokinetics | Cell Proliferation - drug effects | Mice | Mutation | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Mitogen-Activated Protein Kinases - metabolism | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 829 - 840
Summary Background We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in... 
Hematology, Oncology and Palliative Medicine | COLONY-STIMULATING FACTOR | ONCOLOGY | DUCTAL ADENOCARCINOMA | IMMUNOTHERAPY | METAANALYSES | SUPPRESSOR-CELLS | RESISTANT PROSTATE-CANCER | T-CELLS | CHEMOTHERAPY | IPILIMUMAB | TUMOR-ANTIGEN | Cell Proliferation | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fatigue - chemically induced | Pain - chemically induced | Pancreatic Neoplasms - drug therapy | Fluorouracil - administration & dosage | Female | Neutropenia - chemically induced | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Fluorouracil - analogs & derivatives | Cancer Vaccines - administration & dosage | Deoxycytidine - administration & dosage | Pancreatic Ducts | Pancreatic Neoplasms - pathology | Peptide Fragments - administration & dosage | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Cancer Vaccines - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Telomerase - administration & dosage | Disease-Free Survival | Telomerase - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | T-Lymphocytes - immunology | Aged | Peptide Fragments - adverse effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Hospitals | Gemcitabine | Peptides | Pancreatic cancer | Vaccination | Product development | Vaccines | Metastasis | Telomerase | Cancer | Index Medicus
Journal Article